title: Benfluorex: EU marketing authorisation finally withdrawn.
abstract: This amphetamine derivative was marketed for more than 30 years in France despite its lack of tangible efficacy in diabetes and hypertriglyceridaemia, and its potentially severe cardiovascular effects.
mesh_terms: D005062:European Union; D005277:Fenfluramine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005602:France; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D007880:Legislation, Drug; D040541:Marketing / Q000331:legislation & jurisprudence
chemical_list: D000960:Hypolipidemic Agents; D005277:Fenfluramine; C001584:benfluorex